Bifunctional CD22 Ligands Use Multimeric Immunoglobulins as Protein Scaffolds in Assembly of Immune Complexes on B Cells
- 28 May 2008
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
- Vol. 130 (24) , 7736-7745
- https://doi.org/10.1021/ja802008q
Abstract
CD22 is a B cell-specific sialic acid-binding immunoglobulin-like lectin (Siglec) whose function as a regulator of B cell signaling is modulated by its interaction with glycan ligands bearing the sequence NeuAcα2−6Gal. To date, only highly multivalent polymeric ligands (n = 450) have achieved sufficient avidity to bind to CD22 on native B cells. Here we demonstrate that a synthetic bifunctional molecule comprising a ligand of CD22 linked to an antigen (nitrophenol; NP) can use a monoclonal anti-NP IgM as a decavalent protein scaffold to efficiently drive assembly of IgM−CD22 complexes on the surface of native B cells. Surprisingly, anti-NP antibodies of lower valency, IgA (n = 4) and IgG (n = 2), were also found to drive complex formation, though with lower avidity. Ligands bearing alternate linkers of variable length and structure were constructed to establish the importance of a minimal length requirement, and versatility in the structural requirement. We show that the ligand drives assembly of IgM complexes exclusively on the surface of B cells and not other classes of white blood cells that do not express CD22, which lends itself to the possibility of targeting B cells in certain hematopoietic malignancies.Keywords
This publication has 46 references indexed in Scilit:
- Distinct Endocytic Mechanisms of CD22 (Siglec-2) and Siglec-F Reflect Roles in Cell Signaling and Innate ImmunityMolecular and Cellular Biology, 2007
- Siglecs and their roles in the immune systemNature Reviews Immunology, 2007
- ST6Gal-I Restrains CD22-Dependent Antigen Receptor Endocytosis and Shp-1 Recruitment in Normal and Pathogenic Immune SignalingMolecular and Cellular Biology, 2006
- B cells move to centre stage: novel opportunities for autoimmune disease treatmentNature Reviews Drug Discovery, 2006
- Protein Heterodimerization through Ligand-Bridged Multivalent Pre-organization: Enhancing Ligand Binding toward Both Protein TargetsJournal of the American Chemical Society, 2005
- Galectins as modulators of tumour progressionNature Reviews Cancer, 2005
- Cell surface sialic acids do not affect primary CD22 interactions with CD45 and surface IgM nor the rate of constitutive CD22 endocytosisGlycobiology, 2004
- The Ligand-binding Domain of CD22 Is Needed for Inhibition of the B Cell Receptor Signal, as Demonstrated by a Novel Human CD22-specific Inhibitor CompoundThe Journal of Experimental Medicine, 2002
- Large-Scale Synthesis of a Lewis b Tetrasaccharide Derivative, its Acrylamide Copolymer, and Related DI- and Trisaccharides for Use in Adhesion Inhibition Studies with Helicobacter Pylori.Journal of Carbohydrate Chemistry, 1996
- Redirecting the immune response: ligand-mediated immunogenicityJournal of the American Chemical Society, 1991